Aripiprozole-Induced Diplopia: A Case Report

dc.contributor.authorAtli, Abdullah
dc.contributor.authorSelvi, Yavuz
dc.contributor.authorYildiz, Aydin
dc.contributor.authorKaya, Mehmet Cemal
dc.date.accessioned2024-04-24T17:27:38Z
dc.date.available2024-04-24T17:27:38Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractDiplopia is a condition that involves seeing double and impairs quality of life. Acute diplopia can be seen with some general medical drugs and psychotropic drugs. Aripiprazole is a new atypical antipsychotic agent; it has partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. This paper reports development of diplopia, a rare adverse effect of psychotropic drugs, in a 24 year old patient with schizophreniform disorder following use of oral aripiprazole. Clinicians should keep in mind that diplopia may occur with aripiprazole treatment.en_US
dc.identifier.doi10.5455/bcp.20130303114826
dc.identifier.endpage356en_US
dc.identifier.issn1017-7833
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-84891790798
dc.identifier.scopusqualityN/A
dc.identifier.startpage353en_US
dc.identifier.urihttps://doi.org/10.5455/bcp.20130303114826
dc.identifier.urihttps://hdl.handle.net/11468/20109
dc.identifier.volume23en_US
dc.identifier.wosWOS:000339983000009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherKure Iletisim Grubu A Sen_US
dc.relation.ispartofKlinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAripiprazoleen_US
dc.subjectDiplopiaen_US
dc.subjectAdverse Effecten_US
dc.titleAripiprozole-Induced Diplopia: A Case Reporten_US
dc.titleAripiprozole-Induced Diplopia: A Case Report
dc.typeArticleen_US

Dosyalar